News Search Results
May 07, 2025, 20:10 ET 騰盛博藥在2025年EASL大會上公布了其正在進行的ENSURE 2期研究的最新突破數據，表明BRII-179在促進更高的HBsAg清除方面的作用
Elebsiran是一種經皮下注射給藥的靶向乙型肝炎病毒（HBV）的小干擾核糖核酸（siRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。 關於騰盛博藥 騰盛博藥（股票代碼：2137.HK）是一家生物技術公司，致力於針對存在巨大未被滿足的患者需求、治療手段有限，以及給患者帶來嚴重社會歧視的重大公共衛生挑戰開發
More news about: 騰盛博藥生物科技有限公司
May 07, 2025, 18:26 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
May 07, 2025, 16:30 ET Corteva Delivers Strong 1Q 2025, Reaffirms 2025 Outlook
commercialize Corteva's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v)
More news about: Corteva Agriscience
May 07, 2025, 14:53 ET AusperBio Presents Interim Phase IIb AHB-137 Clinical Data in a Late-Breaking Abstract at EASL™ Congress 2025
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from its ongoing Phase IIb trial of AHB-137 in a late-breaking
More news about: AusperBio Therapeutics Inc.
May 07, 2025, 13:15 ET WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering
More news about: WallachBeth Capital LLC
May 07, 2025, 12:00 ET Apertura Gene Therapy Showcases the Progress of its Novel Human Transferrin Receptor AAV Capsid, TfR1 CapX, and Preclinical Programs for Tuberous Sclerosis Complex (TSC) at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
NEW YORK, May 7, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, will showcase significant regulatory, preclinical, and CMC advancements across several oral
More news about: Apertura Gene Therapy
May 07, 2025, 11:50 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
May 07, 2025, 11:02 ET GenoFAB Announces Publication of Groundbreaking Self-Documenting Plasmid Technology In Trends In Biotechnology
Self-Documenting Plasmids has been published in Trends in Biotechnology, introducing a breakthrough technology that could redefine the way plasmids are tracked, verified, and shared in the biotechnology industry. Developed by researchers at Colorado
More news about: GenoFAB
May 07, 2025, 10:30 ET Single Cell Analysis Market worth US$7.56 billion by 2030 with 14.7% CAGR | MarketsandMarkets™
technological developments in single-cell analysis products, the growing focus on the advancement of stem cell research, and the increasing focus on the biotechnology sector. However, the high cost of single-cell analysis products may hamper the growth of the market.
More news about: MarketsandMarkets
May 07, 2025, 10:25 ET INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP
May 07, 2025, 10:15 ET Hollow Fiber Ultrafiltration Market worth $4.85 billion by 2030 - Exclusive Report by MarketsandMarkets™
eliminate bacteria, viruses, and suspended solids without the use of chemicals, hollow fiber ultrafiltration systems are preferred. The growth of the biotechnology, food & beverage, and pharmaceutical sectors—all of which depend on sterile filtration—also contributes to market expansion. The global adoption
More news about: MarketsandMarkets
May 07, 2025, 10:00 ET Eurofins Viracor Revolutionizes Respiratory Diagnostics with New BAL Specimen Type for NeXGen® Fungal / AFB NGS Assay
technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions. Shares in Eurofins Scientific SE are listed on the Euronext
More news about: Viracor Eurofins
May 07, 2025, 09:30 ET Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting
May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research poster
More news about: Hanx Biopharmaceutical Co., Ltd.
May 07, 2025, 09:03 ET Mayo Clinic Study Uses Phenomix AI Algorithm to Predict GLP-1 Side Effects, Advancing Personalized Obesity Care and Drug Development
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning
More news about: Phenomix Sciences
May 07, 2025, 09:00 ET Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture
South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part of its Phase 1/2 clinical trial for CNT201, its recombinant collagenase
More news about: Connext
May 07, 2025, 09:00 ET Supreme Group Acquires Nimble Works and Vital Works, Strengthening Brand Strategy and Creative Execution
Nimble Works and Vital Works are committed to helping clients shape the future of healthcare by advancing innovative biotechnology, precision health, virtual care, digital health, and pharmaceutical products and solutions. We amplify brand voice with on-point positioning and
More news about: Supreme Group
May 07, 2025, 08:45 ET NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has successfully scaled-up its production of
More news about: NeuroSense
May 07, 2025, 08:30 ET Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development
overcoming discovery to first-in-human development challenges and scale-up. Bionova is a flexible and collaborative partner that has worked with leading biotechnology innovators from its new state-of-the-art facility in the San Francisco Bay Area. For more information, visit
More news about: Bionova Scientific
May 07, 2025, 08:05 ET Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting
Orleans, Louisiana. The meeting Is the largest global cell and gene translation conference of the year, with attendees from academia, the biotechnology and pharmaceutical industries.
More news about: Aspen Neuroscience, Inc.
May 07, 2025, 08:00 ET ViVerita Therapeutics Announces Research Collaboration with Boehringer Ingelheim to Accelerate Discovery of Novel Cancer Targets
first-in-class treatment options for patients in need. About ViVerita Therapeutics ViVerita Therapeutics is an early-stage biotechnology company dedicated to discovering a new wave of high-value oncology targets and therapies for the treatment of cancers. With its industry-leading
More news about: ViVerita Therapeutics Inc
May 07, 2025, 08:00 ET Palatin Technologies Announces Pricing of up to $23 Million Public Offering
complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking
More news about: Palatin Technologies, Inc.
May 07, 2025, 08:00 ET BioVaxys and Sona Nanotech Enter Research Collaboration
regulatory approvals. With regards to BioVaxys' and Sona's respective businesses, there are a number of risks that could affect the development of their biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, their lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
May 07, 2025, 07:31 ET BPC Instruments Annual Report for 2024
instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing
More news about: BPC Instruments AB
May 07, 2025, 07:00 ET PAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need
BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for patients with lethal cancers lacking effective treatment options, today announced
More news about: PAQ Therapeutics
May 07, 2025, 07:00 ET PAQ Therapeutics Appoints Andrew Krivoshik, MD, PhD, as Chief Medical Officer, Announces Addition of Eric Rubin, MD, and Piro Lito MD, PhD, to Advisory Board
BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options, today announced that Andrew
More news about: PAQ Therapeutics